A case series of rheumatoid arthritis patients exposed to an etanercept biosimilar during pregnancy: evidence from an increasingly accepted treatment option
Use of the etanercept biosimilar during pregnancy was associated with favourable outcomes, supporting its safety and utility in managing rheumatoid arthritis during pregnancy.
Authors
- Atsuko Murashima (ORCID: https://orcid.org/0000-0002-0569-7172)
- Eiko Miyagawa (ORCID: https://orcid.org/0009-0006-5785-1852)
- Kohei Ogawa (ORCID: https://orcid.org/0000-0002-5672-6308)
- Akitsu Higuchi (ORCID: https://orcid.org/0000-0001-5506-3787)
- Nagayoshi Umehara (ORCID: https://orcid.org/0000-0002-6222-3942)
- Kayoko Kaneko (ORCID: https://orcid.org/0000-0003-3411-5896)
- Nobuaki Ozawa (ORCID: https://orcid.org/0000-0002-1748-1635)
- Chinatsu Takai
- Ayako Kitada
Institutions
- University of Tsukuba (JP)
- National Center For Child Health and Development (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1093/mr/roag021
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00